๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Nanjing
Clinical trial register · China

Clinical Trials in Nanjing, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 41 Nanjing 23 Guangzhou 18 Shanghai 18 Wuhan 14
Narrow the registerReset
Recruitment status
Phase
Site location
Beijing41 Nanjing23 Guangzhou18 Shanghai18 Wuhan14
All 59 locations
Target enrolment
to

Trials with a site in Nanjing

23 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
This Study Evaluates the Diagnostic Performance and Safety of 68Ga-NYM032 PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer.
NCT07649122Prostate Cancer
Norroy Bioscience Co., LTD
Phase 3
232
Nanjing, Wuxi
2026-08-31
Recruiting
Ipsilateral Versus Bilateral Systematic Biopsy Combined With MRI/Ultrasound Cognitive Fusion Targeted Biopsy for Prostate Cancer Diagnosis
NCT07795723Prostate Cancer
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Not applicable
454
Nanjing
2026-07-20
Not yet open
177Lu-PSMA-617 Combined With Darolutamide in Neoadjuvant Treatment of High-risk Localized Prostate Cancer: a Prospective, Single-arm, Multi-center Clinical Trial
NCT07677566Prostate Cancer, Prostate Cancer Patients
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 4
20
Nanjing
2026-07-01
Recruiting
A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer
NCT07230106Prostate Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 2
218
Nanjing, Tianjin
2025-12-08
Recruiting
A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer
NCT07192614Prostate Cancer
AstraZeneca
Phase 1/2
52
Beijing, Chengdu, Guangzhou, Nanjing
2025-09-30
Recruiting
Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
NCT06855277Prostate Cancer
DrugsAAA817·ARPI
Novartis Pharmaceuticals
Phase 3
940
Fuzhou, Guangzhou, Wuhan, Nanjing, Shenyang, Chengdu, Hangzhou, Beijing
2025-07-01
Not yet open
The Diagnostic Application of PSMAPET/MR in Patients Undergoing Secondary Prostate Puncture
NCT06901492PSMA PET/CT, Prostate Cancer, MpMRI
Nanjing First Hospital, Nanjing Medical University
Not applicable
120
Nanjing
2025-06-01
Not yet open
Phase III Clinical Trial to Evaluate INR101 Injection for PET/CT Imaging in Patients With Prostate Cancer.
NCT06922903Prostate Cancer
Yunhe Pharmaceutical (Tianjin) Co., Ltd
Phase 3
240
Beijing, Cangzhou, Wuhan, Yichang, Changsha, Nanjing, Suzhou, Taizhou
2025-04
Recruiting
Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
NCT06780670Prostate Cancer
DrugAAA817
Novartis Pharmaceuticals
Phase 2/3
443
Fuzhou, Wuhan, Nanjing, Shenyang, Xian, Chengdu, Beijing, Guangzhou
2025-02-27
Not yet open
Artificial Intelligence Models for Precision Prediction and Treatment of Prostate Cancer
NCT06662708Prostate Cancer, Prostate Intraductal Carcinoma, Prostate Cancer Aggressiveness, Prostate Cancer Stage
Shao Pengfei
Not applicable
200
Nanjing
2024-12-01
Recruiting
Diagnostic Value of MRI-targeted Plus Index-lesion-ipsilaterally Systematic Biopsy for Biopsy-naive Men At Risk of Prostate Cancer
NCT06584279Prostate Cancer
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Observational
563
Nanjing
2024-10
Recruiting
Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer
NCT06305832Prostate Cancer, Biochemical Recurrence
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2
102
Nanjing
2023-09-07
Recruiting
High Resolution Diffusion Weighted Imaging in Prostate
NCT06636747Prostate Cancer, Prostate Disease
The First Affiliated Hospital with Nanjing Medical University
Observational
500
Nanjing
2023-08-01
Not yet open
Adjutant Apalutamide Plus ADT in Post-RP Patients With High Risk of Recurrence (ARES Study)
NCT05778097Prostate Cancer, Biochemical Recurrence, High Risk
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2
103
Nanjing, Nantong
2023-04-01
Recruiting
Rezvilutamide in Patients With Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer
NCT05753566Prostate Cancer, Biochemical Recurrence
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2
96
Nanjing
2023-03
Active, closed
Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC
NCT04821622Prostate Cancer
Pfizer
Phase 3
599
Hefei, Beijing, Lanzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Nanjing
2021-05-12
Recruiting
MR Microstructural Imaging for Prostate Cancer Diagnosis
NCT07249281Prostate Cancer, Diffusion MRI
First Affiliated Hospital of Zhejiang University
Observational
2,000
Beijing, Zhengzhou, Nanjing, Dalian, Hangzhou
2020-09-01
Recruiting
Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
NCT04221542Prostate Cancer
Amgen
Phase 1
479
Beijing, Guangzhou, Nanchang, Shanghai, Hangzhou, Nanjing, Wenzhou
2020-03-04
Active, closed
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
NCT02960022Prostate Cancer
Astellas Pharma Global Development, Inc.
Phase 2
900
Hubei, Hunan, Nanjing
2016-12-22
Active, closed
A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC
NCT02489318Prostate Cancer
Aragon Pharmaceuticals, Inc.
Phase 3
1,052
Beijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Nanjing, Shanghai
2015-11-27
Rows per page Showing 1–23 of 23
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 27 September 2026. https://priyalifescience.com/clinical-trials-china/city/nanjing

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 23 of those studies with a site in Nanjing that also match the filters currently applied.

How many clinical trials are recruiting in Nanjing?

14 of the 23 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 6 have not yet opened recruitment, 3 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Nanjing), 23 studies
PhaseStudiesRecruitingShare
Phase 27530.4%
Phase 35221.7%
Not applicable4117.4%
Observational3313%
Phase 1114.3%
Phase 1/2114.3%
Phase 2/3114.3%
Phase 4104.3%

Most active sponsors

Lead sponsors with the most studies (Nanjing)
Lead sponsorStudiesRecruiting
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School64
baotai Liang22
Novartis Pharmaceuticals22
Amgen11
Aragon Pharmaceuticals, Inc.10
Astellas Pharma Global Development, Inc.10
AstraZeneca11
First Affiliated Hospital of Zhejiang University11
Jiangsu HengRui Medicine Co., Ltd.11
Nanjing First Hospital, Nanjing Medical University10
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.